Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.
about
Interferons and the Immunogenic Effects of Cancer Therapy.The future of image-guided radiotherapy will be MR guided.A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.Surgery SBRT in retrospective analyses: confounding by operability is the elephant in the room1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
P2860
Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Improved survival with stereot ...... of disruptive randomized data.
@ast
Improved survival with stereot ...... of disruptive randomized data.
@en
type
label
Improved survival with stereot ...... of disruptive randomized data.
@ast
Improved survival with stereot ...... of disruptive randomized data.
@en
prefLabel
Improved survival with stereot ...... of disruptive randomized data.
@ast
Improved survival with stereot ...... of disruptive randomized data.
@en
P2093
P2860
P1476
Improved survival with stereot ...... of disruptive randomized data.
@en
P2093
Brian D Kavanagh
Chad G Rusthoven
Sana D Karam
P2860
P356
10.3978/J.ISSN.2305-5839.2015.06.15
P577
2015-07-01T00:00:00Z